Compare REVB & OBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REVB | OBLG |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.9M |
| IPO Year | N/A | N/A |
| Metric | REVB | OBLG |
|---|---|---|
| Price | $1.15 | $2.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 107.2K | 86.7K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $1.69 |
| 52 Week High | $60.48 | $5.50 |
| Indicator | REVB | OBLG |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 60.41 |
| Support Level | $1.03 | $2.07 |
| Resistance Level | $1.00 | $2.40 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 93.03 | 100.00 |
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Oblong Inc is a provider of patented multi-stream collaboration products and managed services for network solutions and video collaboration. The company's flagship product Mezzanine is the technology platform that defines computing: simultaneous multi-user, multi-screen, multi-device, and multi-location for dynamic and immersive visual collaboration. Mezzanine transforms routine meetings and workflows into agile, engaging experiences by making data visible and accessible in a collaborative setting. The mezzanine enables multiple, concurrent pieces of content to be shared, manipulated, created, and captured across distance. It serves various industries including aerospace, consulting, executive search, broadcast media, technology, financial services, education, healthcare, and real estate.